Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38


Triggering autophagic cell death with a di-manganese(II) developmental therapeutic.

Slator C, Molphy Z, McKee V, Kellett A.

Redox Biol. 2017 Aug;12:150-161. doi: 10.1016/j.redox.2017.01.024. Epub 2017 Feb 4.


Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes.

Riddell IA, Agama K, Park GY, Pommier Y, Lippard SJ.

ACS Chem Biol. 2016 Nov 18;11(11):2996-3001. Epub 2016 Oct 6.


David and Goliath: chemical perturbation of eukaryotes by bacteria.

Ho LK, Nodwell JR.

J Ind Microbiol Biotechnol. 2016 Mar;43(2-3):233-48. doi: 10.1007/s10295-015-1686-6. Epub 2015 Oct 3. Review.


Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).

Gao R, Schellenberg MJ, Huang SY, Abdelmalak M, Marchand C, Nitiss KC, Nitiss JL, Williams RS, Pommier Y.

J Biol Chem. 2014 Jun 27;289(26):17960-9. doi: 10.1074/jbc.M114.565374. Epub 2014 May 7.


Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.

Khiati S, Dalla Rosa I, Sourbier C, Ma X, Rao VA, Neckers LM, Zhang H, Pommier Y.

Clin Cancer Res. 2014 Sep 15;20(18):4873-81. doi: 10.1158/1078-0432.CCR-13-3373. Epub 2014 Apr 8.


ATR checkpoint kinase and CRL1βTRCP collaborate to degrade ASF1a and thus repress genes overlapping with clusters of stalled replication forks.

Im JS, Keaton M, Lee KY, Kumar P, Park J, Dutta A.

Genes Dev. 2014 Apr 15;28(8):875-87. doi: 10.1101/gad.239194.114. Epub 2014 Apr 3.


On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.

Wu CC, Li YC, Wang YR, Li TK, Chan NL.

Nucleic Acids Res. 2013 Dec;41(22):10630-40. doi: 10.1093/nar/gkt828. Epub 2013 Sep 14.


Drugging topoisomerases: lessons and challenges.

Pommier Y.

ACS Chem Biol. 2013 Jan 18;8(1):82-95. doi: 10.1021/cb300648v. Epub 2013 Jan 4. Review.


Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells.

Liu Q, Zhang J, Sun W, Xie QR, Xia W, Gu H.

Int J Nanomedicine. 2012;7:999-1013. doi: 10.2147/IJN.S28088. Epub 2012 Feb 24.


Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs.

Riedl S, Zweytick D, Lohner K.

Chem Phys Lipids. 2011 Nov;164(8):766-81. doi: 10.1016/j.chemphyslip.2011.09.004. Epub 2011 Sep 16. Review.


Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.

Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA.

PLoS One. 2010 Apr 15;5(4):e10186. doi: 10.1371/journal.pone.0010186.


DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.

Pommier Y.

Chem Rev. 2009 Jul;109(7):2894-902. doi: 10.1021/cr900097c. Review. No abstract available.


Targeting DNA topoisomerase II in cancer chemotherapy.

Nitiss JL.

Nat Rev Cancer. 2009 May;9(5):338-50. doi: 10.1038/nrc2607. Epub 2009 Apr 20. Review.


Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.

Richter SN, Giaretta G, Comuzzi V, Leo E, Mitchenall LA, Fisher LM, Maxwell A, Palumbo M.

Nucleic Acids Res. 2007;35(18):6075-85. Epub 2007 Aug 30.


DNA topoisomerase II selects DNA cleavage sites based on reactivity rather than binding affinity.

Mueller-Planitz F, Herschlag D.

Nucleic Acids Res. 2007;35(11):3764-73. Epub 2007 May 21.


Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.

Bruynzeel AM, Abou El Hassan MA, Torun E, Bast A, van der Vijgh WJ, Kruyt FA.

Br J Cancer. 2007 Feb 12;96(3):450-6.


Clerocidin interacts with the cleavage complex of Streptococcus pneumoniae topoisomerase IV to induce selective irreversible DNA damage.

Richter SN, Leo E, Giaretta G, Gatto B, Fisher LM, Palumbo M.

Nucleic Acids Res. 2006 Apr 13;34(7):1982-91. Print 2006.


A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Marchand C, Antony S, Kohn KW, Cushman M, Ioanoviciu A, Staker BL, Burgin AB, Stewart L, Pommier Y.

Mol Cancer Ther. 2006 Feb;5(2):287-95.


Sequence, distance, and accessibility are determinants of 5'-end-directed cleavages by retroviral RNases H.

Schultz SJ, Zhang M, Champoux JJ.

J Biol Chem. 2006 Jan 27;281(4):1943-55. Epub 2005 Nov 22.

Supplemental Content

Support Center